Ardelyx, Inc. (ARDX) gained $5.23, or 36.81%, to $19.44 in mid-day trading today after the company reported positive results from its 371 patient Phase 2b clinical trial evaluating tenapanor. Following the report ARDX price target was raised to $36 from $32 by analysts at Leerink. The firm’s new PT represents expected upside of 84.71% from the stock’s current PPS. Approximately 555,581 shares have already changed hands, compared to the stock’s average daily volume of 36,806 shares.
On valuation-measures, shares of Ardelyx, Inc. have a price/book and forward P/E ratio of 4.14 and 12.05, respectively.Trailing-12 profit margin is (13.80%), while operating margin is 2.08. EPS registers at ($0.12). The company has a market cap of $360.28M and a median Wall Street price target of $29.00 with a high target of $32.00.
On trading-measure, ARDX has a short float of 0.84%. In the past 52 weeks, shares of Fremont, California-based company have traded between a low of $11.37 and a high of $21.60 with the 50-day MA and 200-day MA located at $13.42 and $14.55 levels, respectively.
ARDX currently prints a one year return of 37.87%.
Portola Pharmaceuticals Inc (PTLA) is trading at unusually high volume Wednesday with more than 1.19 million shares changing hands. It is currently at nearly 5x its average daily volume and trading up $3.11, or 12.30%, at $28.48 as of 1:42 p.m. ET. The surge came after the company announced that its first Phase 3 study of andexanet alfa, a potential universal Factor Xa inhibitor antidote and U.S. Food and Drug Administration-designated breakthrough therapy, met its primary and secondary endpoints with high statistical significance. The company said Andexanet alfa was well tolerated with no serious adverse events reported.
On valuation-measures, Portola Pharmaceuticals’ EPS register at ($2.69). Return on assets and equity are (24.80%) and (46.30), respectively. The company has a market cap of $1.18B and a median Wall Street price target of $42.50 with a high target of $45.00.
On trading-measure, PTLA has a beta of -2.72 and a short float of 5.83%. In the past 52 weeks, shares of the biopharmaceuticals company have traded between a low of $19.59 and a high of $31.48 with the 50-day MA and 200-day MA located at $26.73 and $25.39 levels, respectively.
PTLA currently prints a one year loss of about 5.50% and a year-to-date loss of around 1.83%.
Acuity Brands, Inc. (AYI) is currently registering a higher than average trading volume with the issue trading 1.2M shares, compared to the average volume of 416,672. The stock began trading this morning at $125.00 to gain in midday $13.12, or 11.24%, from the prior days close of $117.71. On an intraday basis it has gotten as low as $121.89 and as high as $134.74. The surge came after the company reported 2014 fourth quarter earnings that beat expectations of both revs and eps.
On valuation-measures, shares of Acuity Brands, Inc. have a trailing-12 and forward P/E of 34.22 and 27.05, respectively. P/E to growth ratio is 2.30, while t-12 profit margin is 7.20%. EPS registers at $3.83. The company has a market cap of $5.60B and a median Wall Street price target of $138.00 with a high target of $158.00.
On trading-measure, AYI has a beta of 1.62 and a short float of 3.92%. In the past 52 weeks, shares of Atlanta, Georgia-based lighting solutions provider have traded between a low of $91.61 and a high of $146.28 with the 50-day MA and 200-day MA located at $121.86 and $123.66 levels, respectively.
AYI currently prints a one year return of about 28.35% and a year-to-date return of around 7.89%.
Shares of The New York Times Company (NYT) are up more than 10% to $12.36 in midday trading Wednesday after the company reported that it will cut 100 jobs or 7.5% of its news newsroom staff. The multimedia news and information company also said that in addition to the job cuts, NYT Opinion, a new mobile app dedicated to opinion content, was shutting down “because it was not attracting enough subscribers.”
The New York Times Company, currently valued at $1.86B, has a median Wall Street price target of $13.50 with a high target of $17.50. Approximately 2,757,628 shares have already changed hands, compared to the stock’s average daily volume of 849,147.
In the past 52 weeks, shares of the New York-based company have traded between a low of $11.22 and a high of $17.37 with the 50-day MA and 200-day MA located at $12.09 and $14.43 levels, respectively. Additionally, shares of NYT trade at a P/E ratio of -5.22 and have a Relative Strength Index (RSI) and MACD indicator of 59.11 and -0.08, respectively.
NYT currently prints a one year loss of about 9.73% and a year-to-date loss of around 28.76%.